EXPLORE THE SCIENCE
TL;DR: A 2026 retrospective chart review in Acta Psychiatrica Scandinavica found that a psychiatrist-led metabolic clinic helped 132 of 378 patients with severe mental illness lose at least 5% of baseline body weight over 12 months. Key Findings Clinic outcome…
Read article
TL;DR: A 2026 systematic review and meta-analysis in International Journal of Obesity found that glucagon-like peptide-1 receptor agonists, metabolic drugs that extend a satiety and glucose-control hormone pathway, reduced body weight mainly through fat loss w…
Read article
TL;DR: A 2026 narrative review in Journal of Central Nervous System Disease found that glucagon-like peptide-1 receptor agonists have promising stroke-prevention and animal-model evidence, but human data do not yet support routine use as an acute ischemic stro…
Read article
TL;DR: A 2026 rat study in Neuropsychopharmacology reported that repeated semaglutide treatment reduced cocaine-vs-food choice in male and female rats, supporting further clinical testing for cocaine use disorder rather than proving human benefit. Key Findings…
Read article
TL;DR: A 2026 real-world cohort study in Journal of Diabetes & Metabolic Disorders linked GLP-1 receptor agonists, drugs targeting a glucose-related metabolic hormone pathway, to a higher hazard of new hypersomnolence, but the absolute risk increase was small.…
Read article
Semaglutide Linked to 42% Fewer Psychiatric Hospital Episodes TL;DR: In Swedish registry data covering nearly 100,000 people with depression or anxiety, psychiatric hospital visits and sickness absence were 42% lower during semaglutide treatment periods — with…
Read article
GLP-1 receptor agonists (GLP-1RAs) show promise in regulating the reward system and potentially treating motivation and reward-processing disorders. Highlights: Regulation of Reward System Dysfunction: GLP-1RAs influence the brain’s reward system, which is inv…
Read article
GLP-1 receptor agonists like semaglutide, used for managing Type 2 diabetes, may be linked to adverse mood changes, necessitating further investigation into their psychiatric effects. Highlights: GLP-1 Receptor Agonists: These medications mimic GLP-1 hormone e…
Read article
Semaglutide is emerging as a wonder drug for management of various metabolic diseases. Originally approved for type 2 diabetes, this glucagon like peptide-1 (GLP-1) receptor agonist is now showing promise for treating obesity, non-alcoholic steatohepatitis (NA…
Read article
The FDA-approved diabetes drug semaglutide reduces alcohol drinking in mice and rats, suggesting it could be repurposed as an effective medication for alcohol use disorder (AUD). Key findings include: Semaglutide dose-dependently decreased binge-like drinking…
Read article